The Journal of Heart and Lung Transplantation

Cardiost, Inc. Strengthens Scientific Advisory Board with Renowned Cardiovascular Experts, Advances Prototype Development with OEDIT Grant Support

Retrieved on: 
Friday, September 29, 2023
Medical device, University, Heart failure, Interventional cardiology, Lung transplantation, HF, Johnson & Johnson, Clinical trial, Coronavirus Scientific Advisory Board, Research, The Journal of Heart and Lung Transplantation, Biomedical engineering, Universidad, PCI, Harvard Medical School, IMACS, University of Los Andes (Colombia), CO, Journal, Wallace H. Coulter Department of Biomedical Engineering, User experience, Mount Sinai Medical Center, Publication, Biomedicine, MD, Montefiore Medical Center, Cardiology, Universidad de los Andes, Internal medicine, Fort Collins, Colorado, Journal of Cardiac Surgery, LVAD, Ventricular assist device, Hospital, MCS, Massachusetts General Hospital, CFD, Pharmaceutical industry, Heart, Patient

Cardiost is currently designing an alpha prototype of its LAUD, or Left Atrium Unloading Device, with money it received from Colorado’s OEDIT grant in early 2023.

Key Points: 
  • Cardiost is currently designing an alpha prototype of its LAUD, or Left Atrium Unloading Device, with money it received from Colorado’s OEDIT grant in early 2023.
  • The LAUD is a durable mechanical circulatory support (MCS) device to treat late-stage patients suffering from heart failure (HF).
  • Cardiost is focused on developing cardiovascular devices medical devices in the cardiovascular space.
  • “We are thrilled to add Dr. Goldstein and Dr. Moreno to our Scientific Advisory Board, both KOLs in their respective fields – MCS the former and PCI the latter.

ISHLT Names Prof. Dirk Van Raemdonck as Inaugural Editor-in-Chief for JHLT Open

Retrieved on: 
Wednesday, May 31, 2023
FERS, Checklist, FRCP, Thorax, International Society for Heart and Lung Transplantation, Lung transplantation, GOLD, Research, The Journal of Heart and Lung Transplantation, Doctor of Philosophy, Transplant, MD, Patient, UZ Leuven, Knowledge, Newcastle University, International Society, Microsoft Access, Pharmaceutical industry, Dentistry, Heart

Chicago, IL, May 31, 2023 (GLOBE NEWSWIRE) -- The International Society for Heart and Lung Transplantation (ISHLT) announces the appointment of Dirk Van Raemdonck, MD, PhD, FEBTS, FERS, as the inaugural Editor-in-Chief of JHLT Open, the Society’s new open access journal.

Key Points: 
  • Chicago, IL, May 31, 2023 (GLOBE NEWSWIRE) -- The International Society for Heart and Lung Transplantation (ISHLT) announces the appointment of Dirk Van Raemdonck, MD, PhD, FEBTS, FERS, as the inaugural Editor-in-Chief of JHLT Open, the Society’s new open access journal.
  • JHLT Open is a new journal complementing the venerable Journal of Heart and Lung Transplantation (JHLT), ISHLT’s flagship journal, which is ranked as the number one journal in transplantation by impact factor.
  • "I am deeply honored to be appointed as the Editor-in-Chief for JHLT Open," said Prof. Van Raemdonck.
  • While JHLT Open will be general in content, it will also create opportunities for special virtual issues and programs that highlight specific areas of interest.

Leading Patient Advocacy Groups Launch Honor the Gift Campaign to Oppose Medicare Restrictions to Post-Transplant Diagnostic Testing

Retrieved on: 
Monday, May 15, 2023
Health Resources and Services Administration, Life, Survival, Dialysis, Journal, Patient, Transplant, Sussel-Washington Artist, Mended Hearts, Heart, Gift, Registry, Journal of Thoracic Disease, TRIO, GEP, Ann Harrison (lung transplant recipient), Russell Westbrook, Gene expression profiling, Organization, Lung transplantation, The Journal of Heart and Lung Transplantation, Kidney, Heart transplantation, Legislation, American Society of Transplantation, Multimedia, George Washington University Hospital, International Organization (journal), Organ transplantation, Transplant surgeon, End organ damage, Health, Alport syndrome, Society, International Society, Pharmaceutical industry, Dentistry, Health insurance, Medicare

WASHINGTON, May 15, 2023 /PRNewswire/ -- Leading transplant advocacy groups announced today the re-activation of the Honor the Gift campaign, a coalition dedicated to advocating for greater access and coverage to ensure the long-term health of transplant patients. The reinvigorated campaign, which originally contributed to the successful passage of the Immuno Bill, will take on the latest challenge following Medicare's recent restriction of non-invasive diagnostic tests for solid organ allograft injury. Additionally, the coalition will focus on state and federal policies to protect and expand access to innovative tests that are vital to post-transplant patient's health.

Key Points: 
  • The Honor the Gift campaign will focus first and foremost on restoring Medicare coverage following the March 2023 release of a billing article that restricts coverage of non-invasive post-transplant diagnostic tests like dd-cfDNA and GEP.
  • A recent survey of transplant patients found that 95% believe reduced coverage for non-invasive tests would negatively impact their post-transplant care.
  • "I am proud to be part of the Honor the Gift campaign to advocate for continued coverage.
  • American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons vol.

Researchers confirm successful rehabilitation and recovery of human donor lungs previously deemed unfit for transplant

Retrieved on: 
Monday, January 23, 2023
Vanderbilt University Medical Center, Xenotransplantation, Lung transplantation, State university system, Stanford University, SUNY Downstate Medical Center, Transplant, Surgeon, The Journal of Heart and Lung Transplantation, Hospital, Columbia University, Surgery, Vanderbilt University, Patient, Rehabilitation, Journal, Medical device, Heart

NEW YORK, Jan. 23, 2023 /PRNewswire/ -- A novel method for supporting and recovering donor lungs outside the body shows potential to increase the number of organs available for transplant, according to a recent study published in The Journal of Heart and Lung Transplantation.

Key Points: 
  • The organ shortage crisis is increasingly dire, as thousands of patients die every year waiting to receive donor organs.
  • Despite urgent demand, nearly 80% of donated lungs are too damaged for transplantation, often due to reversible conditions.
  • A promising approach to alleviate the organ shortage involves rehabilitation and recovery of these unutilized donor organs.
  • Results of the study "Technique for xenogeneic cross-circulation to support human donor lungs ex vivo" are reported in The Journal of Heart and Lung Transplantation , and further confirm the efficacy of the technique to rehabilitate human donor lungs initially deemed unfit for transplantation.

New ISHLT Guidelines Support Use of CareDx’s HeartCare Solutions, AlloMap and AlloSure, in Routine Monitoring of Heart Transplant Patients

Retrieved on: 
Wednesday, January 18, 2023
Health, Hospitals, Surgery, Health Technology, General Health, Cardiology, International Society for Heart and Lung Transplantation, University, Journal, DNA, GEP, Patient, Lung transplantation, International Society, Stanford University, The Journal of Heart and Lung Transplantation, Transplant, Heart failure, COVID, Caregiver, Dentistry, Medical device, Heart, International Society for Heart and Lung Transplantation, University, Journal, DNA, GEP, Patient, Lung transplantation, International Society, Stanford University, The Journal of Heart and Lung Transplantation, Transplant, Heart failure, COVID, Caregiver, Dentistry, Medical device, Heart

The new ISHLT guidelines support the use of CareDx’s cardiothoracic portfolio, AlloMap® Heart, AlloSure® Heart, and HeartCare® (AlloMap Heart and AlloSure Heart).

Key Points: 
  • The new ISHLT guidelines support the use of CareDx’s cardiothoracic portfolio, AlloMap® Heart, AlloSure® Heart, and HeartCare® (AlloMap Heart and AlloSure Heart).
  • Specifically, the guidelines:
    Support AlloMap gene-expression profiling (GEP) and donor-derived cell-free DNA (dd-cfDNA) for routine post-transplant monitoring, which is new in the current guidelines and reflects increased adoption of non-invasive molecular testing in clinical practice.
  • This includes dd-cfDNA which is new in the current guidelines.
  • “We applaud ISHLT and the sub-committee for their recognition of the value and importance of innovative, non-invasive solutions, such as AlloSure, AlloMap, and HeartCare, in managing post-heart transplant patients,” said Reg Seeto, CEO and President of CareDx.

First Patients in the World Treated with Impella RP Flex with SmartAssist

Retrieved on: 
Monday, December 5, 2022
Cardiology, Surgery, Health, Medical Devices, Hospitals, Health Technology, Technology, Mobile, Wireless, Sodium bicarbonate, Food, Hackensack University Medical Center, Cardiac arrest, Patient, Pulmonary embolism, Survival rate, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, ABMD, Weaning, Cardiogenic shock, Journal, Multimedia, PMA, The Journal of Heart and Lung Transplantation, HDE, Lung transplantation, Pharmaceutical industry, Medical device, MD, Impella, Heart

Abiomed (Nasdaq: ABMD) announces the first three patients in the world have been treated with Impella RP Flex with SmartAssist, Abiomeds newest heart pump for patients experiencing right heart failure.

Key Points: 
  • Abiomed (Nasdaq: ABMD) announces the first three patients in the world have been treated with Impella RP Flex with SmartAssist, Abiomeds newest heart pump for patients experiencing right heart failure.
  • Dr. Anderson and his colleague Yuriy Dudiy, MD, implanted Impella RP Flex on a 71-year-old patient who was having a minimally invasive valve surgery.
  • Dr. Andersons second Impella RP Flex case involved a 51-year-old patient who experienced cardiac arrest and received Impella support for four days after valve surgery.
  • Impella RP Flex is the latest iteration of the Impella RP heart pump.

Multi-Center, Multi-Society Study of Impella-supported Patients with Cardiogenic Shock due to Myocarditis in Japan Achieves 30-day Survival of 77%

Retrieved on: 
Tuesday, September 20, 2022
Surgery, Medical Devices, Hospitals, Clinical Trials, Health Technology, Cardiology, Biotechnology, Health, General Health, Inflammation, Myocarditis, Journal, COVID-19, Oxygen, JCS, MD, Blood, Muscle tissue, Lung transplantation, Degenerative disease, Heart failure, VA, Survival, Patient, The Journal of Heart and Lung Transplantation, Centers for Disease Control and Prevention, CDC, Cardiogenic shock, Hospital, Multimedia, ABMD, TCT, Pharmaceutical industry, Medical device, Heart, Impella

Abiomed (ABMD) announces the result of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan shows a 30-day survival rate of 77% for patients with cardiogenic shock due to myocarditis.

Key Points: 
  • Abiomed (ABMD) announces the result of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan shows a 30-day survival rate of 77% for patients with cardiogenic shock due to myocarditis.
  • (Graphic: Business Wire)
    The analysis examined 143 consecutive patients with cardiogenic shock due to myocarditis who received Impella support or Impella plus VA ECMO support, known as ECpella.
  • These patients are included in the J-PVAD registry , a registry conducted by 10 Japanese professional societies, including the Japanese Circulation Society (JCS).
  • A previous analysis of myocarditis patients who only received VA ECMO support found 48% survival at 30 days ( Journal of Heart and Lung Transplantation , 2021).

CareDx Unveils New Patient-Centered Medication Management Features on AlloCare Mobile Health App

Retrieved on: 
Thursday, August 4, 2022
Biotechnology, General Health, Other Health, Health, Health Technology, Heart transplantation, Precision medicine, Lung transplantation, Unintentional discharge, Acquisition, Annual report, PLOS, Medication, FACS, Integration, Patient, Bertram Cohler, College, Communication, Surgery, Nasdaq, Liver transplantation, The Journal of Heart and Lung Transplantation, Journal, Research, BCPS, Tampa General Hospital, BMJ Open, Health, Kidney transplantation, Behavioral medicine, Doctor of Pharmacy, Tom Hucker, Immunosuppression, CEO, Medicine, Smartphone, National Kidney and Transplant Institute, Caregiver, Systematic review, Transplant, SEC, Awareness, Medical device, Dentistry, Heart, MD

MedActionPlan PRO is a medication management and adherence platform designed to simplify post-transplant medication regimens.

Key Points: 
  • MedActionPlan PRO is a medication management and adherence platform designed to simplify post-transplant medication regimens.
  • By integrating MedActionPlan PRO into the AlloCare app, participating transplant centers can now push personalized education, medication regimen details, and reminder alerts directly to their patients smartphone.
  • CareDxs strategy of delivering patient-centered digital health solutions to improve the transplant journey has come to fruition with the seamless integration of MedActionPlan PRO with our AlloCare app, said Reg Seeto, CEO and President of CareDx.
  • We are incredibly proud to expand the medication management features on our AlloCare app to help thousands of patients and their clinicians work together to successfully manage complex medication regimens for optimal transplant health and longevity.

Next Generation Advances Science with Research at ISHLT Annual Meeting

Retrieved on: 
Monday, July 25, 2022
Lung transplantation, International Society, 2021 Essex County Council election, Annual general meeting, Research, Philip, Abstract (summary), The Journal of Heart and Lung Transplantation, Machine learning, Transplant, Journal, Disease management, Patient, Medical device, Dentistry, Heart

The 2022 ISHLT Annual Meeting featured more than 1,500 oral and poster presentations, integrating the 10 professional specialties represented within ISHLTa collaborative approach that presents the best of how a multidisciplinary team cares for a patient.

Key Points: 
  • The 2022 ISHLT Annual Meeting featured more than 1,500 oral and poster presentations, integrating the 10 professional specialties represented within ISHLTa collaborative approach that presents the best of how a multidisciplinary team cares for a patient.
  • Each year, ISHLT recognizes the best research being presented at the meeting, highlighting investigators in each of the ISHLT Professional Communities, as well as several awards that focus on early career investigators.
  • The ISHLT Professional Community Awards for Excellence recognize the interdisciplinary contributions made across the care continuum by ISHLT members, encouraging investigation and professional excellence in a wide variety of specialties.
  • These highly scored abstracts are available in a special supplement to the Journal of Heart and Lung Transplantation's April 2022 issue.

JHLT: Tops in Transplantation

Retrieved on: 
Wednesday, June 29, 2022
Patient, Hypertensive emergency, Journal, JCR, Research, Testosterone and the cardiovascular system, International Society for Heart and Lung Transplantation, Internal medicine, Transplant, Lung transplantation, The Journal of Heart and Lung Transplantation, Impact factor, Communication, University, Doctor of Philosophy, Journal Citation Reports, MI, MD, International Society, Hope, Multimedia, Degenerative disease, Education, Medical device, Dentistry, Heart

Journal of Heart and Lung Transplantation increases Impact Factor, maintains #1 ranking among transplantation journals

Key Points: 
  • Journal of Heart and Lung Transplantation increases Impact Factor, maintains #1 ranking among transplantation journals
    JHLT'soverall 2021 Impact Factor is 13.569, up from 10.247 in 2020.
  • ISHLT is the only international interdisciplinary organization focused on interventions for advanced heart and lung disease, including transplantation.
  • The official publication of the International Society for Heart and Lung Transplantation, the Journal of Heart and Lung Transplantation brings readers essential scholarly and timely information in the field of cardiopulmonary transplantation, mechanical and biological support of the failing heart, advanced lung disease (including pulmonary vascular disease) and cell replacement therapy.
  • The International Society for Heart and Lung Transplantation is a not-for-profit, multidisciplinary professional organization dedicated to improving the care of patients with advanced heart or lung disease through transplantation, mechanical support and innovative therapies.